Eli Historical Cash Flow
| LLY Stock | USD 749.92 3.49 0.46% |
Analysis of Eli Lilly cash flow over time is an excellent tool to project Eli Lilly future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Non Cash Items of 2.4 B or Dividends Paid of 4.3 B as it is a great indicator of Eli Lilly ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Eli Lilly latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eli Lilly is a good buy for the upcoming year.
Eli |
About Eli Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Eli balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Eli's non-liquid assets can be easily converted into cash.
Eli Lilly Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Dividends Paid
The total amount of dividends that a company has paid out to its shareholders over a specific period.Capital Expenditures
Capital Expenditures are funds used by Eli Lilly to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Eli Lilly operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Eli Lilly's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Eli Lilly current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Eli Lilly's Change In Cash is fairly stable compared to the past year. Begin Period Cash Flow is likely to rise to about 3.4 B in 2024, whereas Sale Purchase Of Stock is likely to drop (787.5 M) in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 1.9B | 2.5B | 7.4B | 7.8B | Dividends Paid | 3.1B | 3.5B | 4.1B | 4.3B |
Eli Lilly cash flow statement Correlations
Click cells to compare fundamentals
Eli Lilly Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eli Lilly cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | (4.4B) | (500M) | (1.3B) | (1.5B) | (750M) | (787.5M) | |
| Change To Inventory | (258.7M) | (533.4M) | (235.9M) | (599.7M) | (1.4B) | (1.4B) | |
| Change In Cash | (5.7B) | 1.3B | 161.4M | (1.8B) | 751.6M | 789.2M | |
| Free Cash Flow | 3.5B | 4.5B | 5.4B | 4.6B | (3.2B) | (3.0B) | |
| Change In Working Capital | (1.7B) | (747.4M) | (1.0B) | (14.5M) | (3.1B) | (2.9B) | |
| Begin Period Cash Flow | 8.0B | 2.3B | 3.7B | 3.8B | 2.1B | 3.4B | |
| Other Cashflows From Financing Activities | (200.1M) | (241.6M) | (295.9M) | 1.2B | (335M) | (318.3M) | |
| Depreciation | 1.2B | 1.3B | 1.5B | 1.5B | 1.5B | 1.0B | |
| Other Non Cash Items | (3.4B) | (444.2M) | 1.6B | 1.1B | 2.2B | 2.4B | |
| Dividends Paid | 2.4B | 2.7B | 3.1B | 3.5B | 4.1B | 4.3B | |
| Capital Expenditures | 1.4B | 2.0B | 1.9B | 2.5B | 7.4B | 7.8B | |
| Total Cash From Operating Activities | 4.8B | 6.5B | 7.3B | 7.1B | 4.2B | 4.3B | |
| Net Income | 8.3B | 6.2B | 5.6B | 6.2B | 5.2B | 3.1B | |
| Total Cash From Financing Activities | (2.3B) | (3.1B) | (4.1B) | (5.4B) | 3.5B | 3.7B | |
| End Period Cash Flow | 2.3B | 3.7B | 3.8B | 2.1B | 2.8B | 3.4B | |
| Stock Based Compensation | 312.4M | 308.1M | 342.8M | 371.1M | 628.5M | 334.2M | |
| Change To Account Receivables | (127.2M) | (1.4B) | (1.3B) | (299.6M) | (2.5B) | (2.6B) | |
| Total Cashflows From Investing Activities | (8.1B) | (2.3B) | (2.9B) | (3.8B) | (7.2B) | (6.8B) | |
| Other Cashflows From Investing Activities | (7.5B) | 102.8M | 24.3M | (1.2B) | (1.0B) | (1.1B) | |
| Investments | 456.2M | 516.7M | (166M) | (244M) | (7.2B) | (6.8B) | |
| Change Receivables | (357M) | (996.7M) | (127.2M) | (299.6M) | (269.6M) | (283.1M) | |
| Net Borrowings | 4.7B | 291.6M | 501.4M | (62M) | (71.3M) | (67.7M) | |
| Cash And Cash Equivalents Changes | 2.0B | 1.5B | (5.7B) | (1.6B) | (1.4B) | (1.4B) | |
| Cash Flows Other Operating | (590.1M) | (980M) | (602.3M) | (793.5M) | (714.2M) | (678.4M) | |
| Change To Netincome | 653.3M | (270.6M) | 1.2B | (668.4M) | (601.6M) | (571.5M) | |
| Change To Liabilities | (699M) | 1.3B | (664.1M) | 1.7B | 1.9B | 2.0B | |
| Change To Operating Activities | (602.3M) | (457.1M) | 1.5B | (793.5M) | (714.2M) | (678.4M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.